^
Association details:
Biomarker:KMT2C mutation
Cancer:Solid Tumor
Drug Class:Immunotherapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumors

Excerpt:
...we validated the predictive potential of KMT2A/C mutations in an expanded ICI-treated cohort (n = 1395). KMT2A/C-mutant patients achieved better OS compared with KMT2A/C-wildtype patients (HR = 0.68, P = 0.003); and the survival advantages appeared in the majority of cancer subtypes.
DOI:
10.1186/s40364-020-00241-0